ABTL-0812 is a Small Molecule owned by Ability Pharmaceuticals, and is involved in 6 clinical trials, of which 3 were completed, 1 is ongoing, and 2 are planned.
ABTL-0812 acts by inhibiting gene expression of AKT, PI3K and mTORC1/C2 pathway which are involved in protein synthesis and cell survival. It also inhibits DNA synthesis by blocking the expression of dihydrofolate reductase (DHFR) needed for cell proliferation. Blocking these two cellular functions leads to the death of tumor cells through autophagy.
The revenue for ABTL-0812 is expected to reach a total of $135m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the ABTL-0812 NPV Report.
ABTL-0812 is under development for the treatment of advanced solid tumors including pancreatic cancer, biliary tract cancer, lung carcinoma, endometrial cancer, non-small cell lung cancer, adult and pediatric neuroblastoma, glioblastoma. It is administered orally. The drug candidate targets AKT, PI3K, dihydrofolate reductase (DHFR) and mTORC1/C2 and is developed based on membrane lipid therapy. It was also under development for the treatment of breast cancer and glioma.
SciClone Pharmaceuticals Holdings Overview
SciClone Pharmaceuticals Holdings (SciClone) develops and commercializes products for the treatment of cancer and immunology. The company’s pipe line products include daya sin, zotye, nomic, angel, ando student, he lesheng, mesna, methotrexate injection, algos and faroda among others. Its under-development products comprise Naxitamab, Circumcising, Vibativ, Vaborem, RRx-001, PEN-866, PT-112, ABTL-0812 and HSP90-PI3K. It also markets Zadaxin (Thymalfasin), an immunostimulatory agent indicated for the treatment of hepatitis as an immune system enhancer. SciClone is headquartered in Hongkong.
The company reported revenues of (Renminbi) CNY2,518.5 million for the fiscal year ended December 2021 (FY2021), an increase of 31.3% over FY2020. In FY2021, the company’s operating margin was 42%, compared to an operating margin of 43.5% in FY2020. In FY2021, the company recorded a net margin of 36.7%, compared to a net margin of 39.3% in FY2020.
Quick View – ABTL-0812
|Highest Development Stage|